A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Cancer
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
Completed
- Amsterdam
- Ankara
- Antwerpen
- Atlanta
- Aurora
- Badalona
- Baltimore
- Banja Luka
- Barcelona
- Basel
- Boston
- Breda
- Brest
- Bruxelles
- Caen
- Charleroi
- Charlottesville
- Chicago
- Chuo City
- Cincinnati
- Cleveland
- Columbus
- Duarte
- Essen
- Fort Myers
- Fukuoka
- Gilbert
- Groningen
- Großhansdorf
- Habikino
- Heidelberg
- Hershey
- Hirakata
- Hong Kong Island
- Houston
- Huntersville
- İzmir
- Lausanne
- Lebanon
- Leuven
- Limoges
- Ljubljana
- London
- Los Angeles
- Lyon
- Madison
- Malatya
- Marietta
- Melbourne
- Meldola
- Milano
- Minato City
- Montpellier
- Nashville
- Nedlands
- New Haven
- New Hyde Park
- New Territories
- New York
- Nürnberg
- Oldenburg
- Orlando
- Osaka
- Oshawa
- Ottawa
- Philadelphia
- Plovdiv
- Port St. Lucie
- Sagamihara
- Saint-Herblain
- Salt Lake City
- Sanatorio San Luigi
- Sarajevo
- Scottsdale
- Seattle
- Sendai
- Sevilla
- Singapore
- Sofia
- South Pasadena
- St Leonards
- St. Gallen
- St. Louis
- St. Petersburg
- Stanford
- Strasbourg
- Sutton
- T'bilisi
- Toronto
- Vancouver
- Villejuif
- Villingen-Schwenningen
- Washington
- Woolloongabba
- Yokohama
- Zürich
- 横浜市
NCT02031458 2013-003330-32 GO28754
Trial Summary
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Eligibility Criteria
- Adult participants greater than or equal to 18 years of age
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
- Measurable disease, as defined by RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:
Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1
- Central nervous system (CNS) disease, including treated brain metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted
- Active hepatitis B or hepatitis C
- Human Immunodeficiency virus (HIV) positive
- Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
For the latest version of this information please go to www.forpatients.roche.com